FFilingSight

Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.

Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →

DexCom Inc.

DXCMHealthcare

Generated Aug 19, 2026, 11:17 PM UTC

analytical score 19

DXCM (DexCom Inc.) analytical snapshot. Revenue grew +15.6% YoY to $4.66B. Net margin at 17.94% (expanding ▲). Return on equity 30.46%, ROA 13.19%, ROIC 33.20%. Market cap $33.92B at $89.88 per share. Trailing P/E 43.00, P/S 7.28, P/B 12.94. EV/Operating income ≈ 35.99 (EV $32.82B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score 19 (data confidence 84%). Descriptive analytics from public filings — not investment advice.

Market cap
$33.92B
377.36M shares
Price
$89.88
NMS
P/E (ttm)
43.00
Revenue (FY)
$4.66B
YoY +15.6%
Net margin
17.94%
▲ 6.21pp
Free cash flow
$1.08B
23.11% margin
Risk level
Moderate

Free SEC analysis

— computed from SEC filings, free to read
Free previewRegulatory Analyst

Filings & Ownership

Regulatory Analyst
score 20Improving
80% conf

Latest annual report (10-K) filed Feb 12, 2026. Latest quarterly report (10-Q) filed Jul 30, 2026. 13 recent 8-K material-event filings in the index.

  • Latest annual report (10-K) filed Feb 12, 2026.
  • Latest quarterly report (10-Q) filed Jul 30, 2026.
  • 13 recent 8-K material-event filings in the index.
  • Recent insider Form 4s: 0 buy vs 0 sell transactions.
  • ~10,000+ recent 13F-HR filings reference DexCom Inc.; broad institutional reporting.
  • Recent filers include PURA VIDA INVESTMENTS, LLC, Rothschild Capital Partners, LLC, WS MANAGEMENT LLLP.
  • 20 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 12, 2026
Annual report
Latest 10-Q
Jul 30, 2026
8-K (recent)
13
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
0
Recent 13F institutional filers (SEC EDGAR full-text)
FilerFormFiled
PURA VIDA INVESTMENTS, LLC13F-HRNov 14, 2017
Rothschild Capital Partners, LLC13F-HRMay 4, 2016
WS MANAGEMENT LLLP13F-HRMay 11, 2023
WS MANAGEMENT LLLP13F-HRNov 13, 2023
BRAIDWELL LP13F-HRNov 14, 2024
Recent 8-K material events
DateFormDescription
Jul 30, 20268-K8-K
May 28, 20268-K8-K
May 15, 20268-K8-K
Apr 30, 20268-K8-K
Mar 2, 20268-K8-K
Feb 26, 20268-K8-K
Feb 12, 20268-K8-K
Jan 12, 20268-K8-K
Sources:SEC EDGAR — Company FilingsSEC EDGAR — Full-Text Search
Free previewSEC Filing Analyst

SEC Filing Deep-Analysis

SEC Filing Analyst
score -5Stable
72% conf

1 positive signal(s), 2 watch item(s) detected from XBRL filing diff analysis. 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.

  • Operating cash flow exceeds net income: OCF is 1.72x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
  • NEW: Impairment charge: Impairment charge appears in recent filings but not in the prior 24-month period. Monitor for materiality.
  • NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
  • Endogenous analysis: 1 positive signal(s) versus 0 risk signal(s). The filing exhibits more constructive indicators than concerns, though individual risk factors should still be monitored.
  • 6 new XBRL disclosure(s) in latest filing — expanding reporting scope.
  • 20 disclosure(s) dropped from prior year — reduced reporting granularity.
  • 2 new risk-language term(s) detected in filing text: Impairment charge, Off-balance sheet arrangements.
Revenue
$4.66B
+15.6% YoY
Gross profit
$2.80B
+14.9% YoY
Operating income
$911.8M
+52.0% YoY
Net income
$836.3M
+45.1% YoY
Operating cash flow
$1.44B
+45.6% YoY
Capex
$363.5M
+1.3% YoY
Total assets
$6.34B
-2.2% YoY
Total liabilities
$3.59B
-18.0% YoY
Filing quality score
80/100
6 new disclosures
SEC XBRL metric changes (latest annual vs prior)
MetricPrior yearLatest yearChange% Change
Revenue$4.03B$4.66B$629.0M+15.6%
Gross profit$2.44B$2.80B$363.7M+14.9%
Operating income$600.0M$911.8M$311.8M+52.0%
Net income$576.2M$836.3M$260.1M+45.1%
Operating cash flow$989.5M$1.44B$451.2M+45.6%
Capex$358.8M$363.5M$4.7M+1.3%
Total assets$6.48B$6.34B$-144.6M-2.2%
Total liabilities$4.38B$3.59B$-788.0M-18.0%
Long-term debt$6.8M$4.6M$-2.2M-32.4%
Cash & equivalents$606.1M$917.7M$311.6M+51.4%
Stockholders equity$2.10B$2.75B$643.4M+30.6%
Inventory$542.6M$629.1M$86.5M+15.9%
Accounts receivable$1.01B$1.22B$210.4M+20.9%
R&D expense$552.4M$599.1M$46.7M+8.5%
SG&A expense$1.29B$1.29B$5.2M+0.4%
Interest expense$14.9M$14.3M$-600000-4.0%
XBRL disclosure changes (new vs dropped concepts)
TypeConcepts
AddedAdjustmentsRelatedToTaxWithholdingForShareBasedCompensation, EquitySecuritiesWithoutReadilyDeterminableFairValueAmount, EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount, FiniteLivedIntangibleAssetsPeriodIncreaseDecrease, PaymentsRelatedToTaxWithholdingForShareBasedCompensation, PaymentsToAcquireBusinessesNetOfCashAcquired
RemovedAccountsReceivableGross, AccountsReceivableNet, AccruedIncomeTaxesNoncurrent, AdvertisingExpense, AllowanceForDoubtfulAccountsReceivable, AmortizationOfIntangibleAssets, AvailableForSaleDebtSecuritiesAmortizedCostBasis, AvailableForSaleSecuritiesDebtSecurities, AvailableForSaleSecuritiesDebtSecuritiesCurrent, AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
Risk language in filing text (EDGAR full-text search)
TermSeverityRecentPriorStatus
Impairment chargemedium50NEW
Restructuringmedium57Ongoing
Off-balance sheet arrangementsmedium50NEW
Related party transactionslow52Ongoing
Filing signal breakdown
Red flags: 0
Positive: 1
Watch: 2
Red flags
Positive
Watch
Sources:SEC EDGAR — Company Facts (XBRL)SEC EDGAR — Financial Reports
Free previewFundamentals Analyst

Fundamentals

Fundamentals Analyst
score 95Improving
80% conf

Revenue grew +15.6% YoY to $4.66B. Net margin at 17.94% (expanding ▲). Return on equity 30.46%, ROA 13.19%, ROIC 33.20%.

  • Revenue grew +15.6% YoY to $4.66B.
  • Net margin at 17.94% (expanding ▲).
  • Return on equity 30.46%, ROA 13.19%, ROIC 33.20%.
  • Gross margin 60.10%, operating margin 19.56%.
  • Free cash flow margin 23.11% ($1.08B).
  • Net income up ▲ +45.1% YoY.
  • Debt/equity 0.00, current ratio 1.73, net debt -$1.10B.
  • Asset turnover 0.72 — capital efficiency.
Revenue (FY)
$4.66B
YoY +15.6%
Net margin
17.94%
▲ 6.21pp
ROE
30.46%
ROA 13.19%
ROIC
33.20%
EPS (diluted)
$2.09
FY2025
Free cash flow
$1.08B
23.11% margin
Debt / equity
0.00
Cash $1.10B
Current ratio
1.73
Equity $2.62B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
FYRevenueRev YoYGross%Op%Net%FCFROE%
2024$4.03B+11.3%60.4614.8814.29$630.7M27.40
2025$4.66B+15.6%60.1019.5617.94$1.08B30.46
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
Quarter endRevenueYoYQoQNet margin
Mar 31, 2017$142.3M+22.5%—-29.30%
Jun 30, 2017$170.6M+24.3%+19.9%1.70%
Sep 30, 2017$184.6M+24.2%+8.2%-1.08%
Mar 31, 2018$184.4M+29.6%-0.1%-13.12%
Jun 30, 2018$242.5M+42.1%+31.5%12.45%
Sep 30, 2018$266.7M+44.5%+10.0%17.47%
Sources:SEC EDGAR — Company Facts (XBRL)
+8 more years of history, charts & full breakdown Pro

Pro analysis — preview

— score, signals & key metrics shown; full reasoning locked

Valuation

Valuation Analyst
score -60Deteriorating
95% conf

Market cap $33.92B at $89.88 per share. Trailing P/E 43.00, P/S 7.28, P/B 12.94. EV/Operating income ≈ 35.99 (EV $32.82B).

  • Market cap $33.92B at $89.88 per share.
Market cap
$33.92B
377.36M shares
P/E (ttm)
43.00
P/S
7.28
P/B
12.94
EV
$32.82B
Intrinsic (DCF)
$49.11
-45.4% vs price
ProFull breakdown & reasoning locked

Price & Technicals

Technical Analyst
score 50Improving
85% conf

Price $89.88 — uptrend (above 200-DMA); 1-month momentum positive. RSI(14) 75.50 (overbought).

  • Price $89.88 — uptrend (above 200-DMA); 1-month momentum positive.
Price
$89.88
NMS
RSI(14)
75.50
50-DMA
$77.04
200-DMA
$69.00
Volatility (ann.)
42.72%
52w range
$54.11–$91.96
-2.3% from high
ProFull breakdown & reasoning locked

Macro & Rates

Macro Analyst
score 30Improving
80% conf

Risk-on · Supportive. Real GDP growth 1.50% (quarterly, as of Apr 1, 2026). CPI inflation +3.3% YoY. Fed funds rate 3.63%, 10Y Treasury 4.71%.

  • Market regime: Risk-on · Supportive.
GDP growth
1.50%
CPI (YoY)
+3.3%
Fed funds
3.63%
10Y yield
4.71%
10Y−2Y
0.46pp
Unemployment
4.10%
ProFull breakdown & reasoning locked

Risk Scorecard

Risk Analyst
score -10Stable
90% conf

Composite risk Moderate. Leverage debt/equity 0.00 (low). Liquidity current ratio 1.73 (adequate).

  • Composite risk: Moderate.
Risk level
Moderate
Debt / equity
0.00
Current ratio
1.73
Margin stdev
56.70pp
Cash / assets
17.12%
Liab / assets
59.39%
ProFull breakdown & reasoning locked

See the full picture behind every stock

Unlock the complete 10-year fundamentals, DCF & Graham intrinsic value, 13F/13D ownership flow, risk scorecard, multi-analyst bull/bear debate — plus watchlist alerts and your research workspace. Start with a 14-day Pro trial.

Subscribe to ProCreate free account

3 sections free · 4 Pro previews · composite 19

Macro exposure

Defensive · Low sensitivity
Neutral

Macro regime: Risk-on · Supportive. DexCom Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.

Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
15.84
Fed funds
3.63%
CPI YoY
+3.3%

Analytical read

deterministic preview

Revenue grew **+15.6%** YoY to $4.66B..

Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Open analytical workspace

Peer comparison

Defensive group

How DXCM stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.

CompanyScoreMacro
DexCom Inc. DXCM● you19Neutral
Bristol-Myers Squibb BMY19Neutral
Eli Lilly & Co. LLY17Neutral
HCA Healthcare HCA9Neutral
Gilead Sciences GILD8Neutral
Johnson & Johnson JNJ8Neutral
Abbott Laboratories ABT7Neutral
Biogen Inc. BIIB7Neutral
Intuitive Surgical Inc. ISRG7Neutral
Coca-Cola Co. KO6Neutral
Zoetis Inc. ZTS6Neutral
Thermo Fisher Scientific TMO3Neutral
Regeneron Pharmaceuticals REGN3Neutral
Danaher Corp. DHR1Neutral
Merck & Co. MRK0Neutral
Illumina Inc. ILMN0Neutral
Colgate-Palmolive CL-2Neutral
Vertex Pharmaceuticals VRTX-2Neutral
AbbVie Inc. ABBV-7Neutral
Procter & Gamble PG-7Neutral
CVS Health Corp. CVS-8Neutral
Walmart Inc. WMT-8Neutral
Mondelez International MDLZ-10Neutral
Amgen Inc. AMGN-10Neutral
Cigna Group CI-11Neutral
Kroger Co. KR-12Neutral
Costco Wholesale COST-14Neutral
Pfizer Inc. PFE-15Neutral
PepsiCo Inc. PEP-16Neutral
Sysco Corp. SYY-16Neutral
Hershey Co. HSY-17Neutral
Kimberly-Clark Corp. KMB-18Neutral
Moderna Inc. MRNA-21Neutral
UnitedHealth Group UNH-25Neutral